Biocon

Q4 FY26Pharmaceuticals & Biotechnology

Biocon Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹416

Market cap₹67.7K Cr

P/E93.1

Updated23 Aug 2026

Read4 min read

The short version

Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28. - Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27. - U.S. Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.

From Biocon's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Biosimilars revenue expected to grow as recent launches start scaling, especially in the second half of FY '27 and into FY '28.
Insulin franchise shows strong growth with global sales crossing $300 million; expanded capacity to support further uplift starting H2 FY '27.
U.S. biosimilar business to gain momentum with launches like aflibercept (Yesafili) expected in H2 FY '27.
Generics business to scale up with improvements in profitability driven by higher volume and operating leverage; pipeline includes several upcoming launches.
Operating leverage to improve as capacity utilization rises in both biosimilars and generics.
Overall volume growth is steady, with a strong focus on sustainable and profitable expansion across all geographies.

2 more points management made on revenue & sales performance

Profitability & Margins

Biosimilars and generics businesses are expected to scale up meaningfully in FY '27 and FY '28, supporting growth and operating leverage.
Sequential growth in biosimilars revenue noted (12% increase from Q3 to Q4 FY '26), with further ramp-up expected in the second half of FY '27.
Margin improvements anticipated due to better capacity utilization and operating leverage as generics scale.
EBITDA growth and margin expansion expected, building on a 33% YoY EBITDA growth (Q4 FY '26) and a 26% EBITDA margin in biosimilars.
Interest cost savings from deleveraging will enhance profitability and cash generation from FY '27 onward.
Profitably sustainable growth prioritized over rapid market share gains, aiming for consistent margin profile improvement.

2 more points management made on profitability & margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete. (Page 5)
The Malaysia facility capacity is being doubled for both drug substance and drug product, with drug product line qualification happening currently and drug substance doubling by end of FY '26. (Pages 15-16)
Minor debottlenecking at Bangalore may occur but no large greenfield capex is planned for FY '27 or FY '28. (Page 15)
Future capital allocation focus will be on profitable and sustainable growth, not large new expansions. (Page 19)

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential

1Accretion Pharmaceuticals Ltd₹226 Cr

Rev 1Mar 2

2OneSource Specialty Pharma Ltd₹17.3K Cr

Rev 1Mar 3

3₹490 Cr

Rev 2Mar 1

4₹297 Cr

Rev 2Mar 1

5₹6.7K Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any planned new fundraising through debt or equity in the provided text.
The company highlighted that the major capital investment phase is substantially complete, with focus now on execution and operating leverage.
They emphasized deleveraging as a priority, with all free cash flow planned to reduce net debt further.
Interest cost savings are being realized, with a strengthened balance sheet post-merger.

2 more points management made on fundraising & capital structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript excerpts do not contain specific details regarding the current or expected orderbook or pending orders for Biocon Limited. The discussion mainly focuses on biosimilar sales breakdown, product performance, capacity utilization, financial results, capital expenditure, and strategic priorities. No explicit commentary or quantitative data related to order book or pending orders is mentioned on the available pages. For precise information on the current or expected orderbook or pending orders, please refer to other sections of the full earnings report or investor presentation not included here.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Biocon's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Biocon Q4 FY26 results?

What is Biocon share price analysis?

Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

The heavy lifting on capital investments is largely behind Biocon; major investment phases are substantially complete.

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.